Ju‐Whei Lee
YOU?
Author Swipe
View article: Overall side‐effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments
Overall side‐effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments Open
Background Overall side‐effect impact, the aggregated experience of multiple toxicities, can be captured with the single Functional Assessment of Cancer Therapy (FACT) item GP5 (“I am bothered by side effects of treatment”). The objective …
View article: Data from Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials
Data from Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials Open
Background: While cigarette smoking has declined among the US general population, sale and use of non-cigarette alternative tobacco products (ATPs; e.g., e-cigarettes, cigars) and dual use of cigarettes/ATPs are rising. Little is known abo…
View article: Supplemental Table 1 from Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials
Supplemental Table 1 from Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials Open
Supplemental Table 1 shows cancer types, patient accrual and survey completion rates for parent trials
View article: Supplemental Table 2 from Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials
Supplemental Table 2 from Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials Open
Supplemental Table 2 shows associations of baseline continuous participant characteristics with past 30-day tobacco product use
View article: Supplemental Table 2 from Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials
Supplemental Table 2 from Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials Open
Supplemental Table 2 shows associations of baseline continuous participant characteristics with past 30-day tobacco product use
View article: Supplemental Table 1 from Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials
Supplemental Table 1 from Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials Open
Supplemental Table 1 shows cancer types, patient accrual and survey completion rates for parent trials
View article: A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol
A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol Open
Introduction Relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) remains a therapeutic challenge. Preclinical data in both B‐ and T‐ALL suggests synergy of venetoclax (VEN) with vincristine (VCR).…
View article: Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma Open
Importance There is substantial interest in capturing cancer treatment tolerability from the patient’s perspective using patient-reported outcomes (PROs). Objective To examine whether a PRO question, item 5 from the Functional Assessment o…
View article: Supplemental Table 1 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials
Supplemental Table 1 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials Open
Supplemental Table 1 shows cancer types, patient accrual and survey completion rates for parent trials
View article: Supplemental Table 2 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials
Supplemental Table 2 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials Open
Supplemental Table 2 shows associations of baseline continuous participant characteristics with past 30-day tobacco product use
View article: Supplemental Table 2 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials
Supplemental Table 2 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials Open
Supplemental Table 2 shows associations of baseline continuous participant characteristics with past 30-day tobacco product use
View article: Data from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials
Data from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials Open
Background:While cigarette smoking has declined among the U.S. general population, sale and use of non-cigarette alternative tobacco products (ATP; e.g., e-cigarettes, cigars) and dual use of cigarettes/ATPs are rising. Little is known abo…
View article: Supplemental Table 1 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials
Supplemental Table 1 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials Open
Supplemental Table 1 shows cancer types, patient accrual and survey completion rates for parent trials
View article: Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial
Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial Open
PURPOSE Despite defined grades of 1 to 5 for adverse events (AEs) on the basis of Common Terminology Criteria for Adverse Events criteria, mild (G1) and moderate (G2) AEs are often not reported in phase III trials. This under-reporting may…
View article: Data from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials
Data from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials Open
Background:While cigarette smoking has declined among the U.S. general population, sale and use of non-cigarette alternative tobacco products (ATP; e.g., e-cigarettes, cigars) and dual use of cigarettes/ATPs are rising. Little is known abo…
View article: Supplemental Table 2 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials
Supplemental Table 2 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials Open
Supplemental Table 2 shows associations of baseline continuous participant characteristics with past 30-day tobacco product use
View article: Supplemental Table 1 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials
Supplemental Table 1 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials Open
Supplemental Table 1 shows cancer types, patient accrual and survey completion rates for parent trials
View article: Supplemental Table 1 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials
Supplemental Table 1 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials Open
Supplemental Table 1 shows cancer types, patient accrual and survey completion rates for parent trials
View article: Data from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials
Data from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials Open
Background:While cigarette smoking has declined among the U.S. general population, sale and use of non-cigarette alternative tobacco products (ATP; e.g., e-cigarettes, cigars) and dual use of cigarettes/ATPs are rising. Little is known abo…
View article: Supplemental Table 2 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials
Supplemental Table 2 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials Open
Supplemental Table 2 shows associations of baseline continuous participant characteristics with past 30-day tobacco product use
View article: Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials
Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials Open
Background: While cigarette smoking has declined among the U.S. general population, sale and use of non-cigarette alternative tobacco products (ATP; e.g., e-cigarettes, cigars) and dual use of cigarettes/ATPs are rising. Little is known ab…
View article: Supplementary Figure 4 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Supplementary Figure 4 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303 Open
PDF file - 55K, Kaplan-Meier estimates of (a) overall survival, (b) progression-free survival by NRAS and ERK cluster status.
View article: Supplementary Figure 3 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Supplementary Figure 3 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303 Open
PDF file - 53K, Kaplan-Meier estimates of (a) overall survival, (b) progression-free survival by PIK3CA, PTEN, and Akt cluster status.
View article: Supplementary Table 2 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Supplementary Table 2 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303 Open
PDF file - 64K, Summary of Biomarker AQUA Scores at Baseline.
View article: Supplementary Figure 2 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Supplementary Figure 2 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303 Open
PDF file - 61K, Kaplan-Meier estimates of (a) overall survival, (b) progression-free survival by PIK3CA, NRAS, and PTEN cluster status.
View article: Supplementary Table 3 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Supplementary Table 3 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303 Open
PDF file - 67K, Odds Ratio and Hazard Ratio (with 95% Confidence Interval) with A Unit Increase in the Form of log10 Transformation in AQUA Scores by Biomarker.
View article: Supplementary Table 2 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Supplementary Table 2 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303 Open
PDF file - 64K, Summary of Biomarker AQUA Scores at Baseline.
View article: Supplementary Figure 2 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Supplementary Figure 2 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303 Open
PDF file - 61K, Kaplan-Meier estimates of (a) overall survival, (b) progression-free survival by PIK3CA, NRAS, and PTEN cluster status.
View article: Supplementary Table 1 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Supplementary Table 1 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303 Open
PDF file - 81K, Primary antibodies Used for Immunohistochemistry.
View article: Data from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Data from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303 Open
Purpose: We sought to evaluate the correlation between tissue biomarker expression (using standardized, quantitative immunofluorescence) and clinical outcome in the E2303 trial.Experimental Design: Sixty-three eligible patients with operab…